Alcon Acquired by Novartis
On December 15, 2010, Novartis (NYSE: NVS) agreed to acquire the remaining shares of Alcon, Inc. (NYSE: ACL) it doesn't currently own for $168 per share.
The merger consideration will be comprised of a combination of Novartis shares and, if necessary, a cash contingent value amount to result in a total value of $168 per share.
Upon completion of the merger, Alcon will become the second largest division within Novartis. CIBA VISION and select Novartis ophthalmic medicines will be integrated into Alcon, forming an organization with more than $8.7 billion in sales covering over 70 percent of the eye care segment.
The merger consideration will be comprised of a combination of Novartis shares and, if necessary, a cash contingent value amount to result in a total value of $168 per share.
Upon completion of the merger, Alcon will become the second largest division within Novartis. CIBA VISION and select Novartis ophthalmic medicines will be integrated into Alcon, forming an organization with more than $8.7 billion in sales covering over 70 percent of the eye care segment.
View Older Stories View More Recent Stories
-
Publicis Groupe: 2019 Annual Results
-
Publicis Groupe: 2019 Annual Results
-
Publicis Groupe: 2019 Full Year Results
-
Aequus and Medicom Announce Changes to their Respective Commercial Leadership Teams
-
Aequus and Medicom Announce Changes to their Respective Commercial Leadership Teams
-
Novartis delivered strong sales growth, margin expansion and breakthrough innovation launching five NMEs in 2019
-
US Pharma Development Veteran Dr. Richard Malamut Joins the Medical Advisory Board of MedinCell
-
Amneal Appoints Jeff George, John Kiely and Shlomo Yanai to Board of Directors
-
WeedMD Appoints Seasoned Management Team to Lead Commercial Extraction Affiliate CX Industries Inc.
-
Alcon Reports Third Quarter and Nine Months 2019 Results
-
Alcon Reports Third Quarter and Nine Months 2019 Results
-
Atlas Nanotech Targets the World’s Largest Consumer Health Products Companies to License the FirstEver Nanotechnology Vitamin A (Retinol) Based Crystalline Eye Drop
-
Precision BioSciences (DTIL) Announces Kevin J. Buehler to Board
-
Precision BioSciences Welcomes Healthcare Industry Expert, Kevin J. Buehler, to its Board of Directors
-
Precision BioSciences Welcomes Healthcare Industry Expert, Kevin J. Buehler, to its Board of Directors
-
Novartis delivered another strong quarter with double digit sales growth and core1 margin expansion; 2019 sales and profit guidance raised; Beovu launched in US
-
Alcon Contact Lens and Cataract Innovations to Headline Clinical and Educational Program at #Academy19
-
Alcon Contact Lens and Cataract Innovations to Headline Clinical and Educational Program at #Academy19
-
2e CEO, Ross Toohey, Wins Silver MM&M Agency Entrepreneur Of The Year
-
Alcon to Highlight AcrySof IQ PanOptix Trifocal IOL Launch and Groundbreaking IOL Data at American Academy of Ophthalmology Annual Meeting
-
Alcon to Highlight AcrySof IQ PanOptix Trifocal IOL Launch and Groundbreaking IOL Data at American Academy of Ophthalmology Annual Meeting
-
Ophthalmic Lasers Market to Reach US$ 722.0 Mn by 2026
-
Alcon Reports Second Quarter and First Half 2019 Results
-
Alcon Reports Second Quarter and First Half 2019 Results
-
Alcon to Launch PRECISION1 Daily Disposable Contact Lenses as it Continues to Deliver on Vision Care Pipeline
-
Alcon to Launch PRECISION1 Daily Disposable Contact Lenses as it Continues to Deliver on Vision Care Pipeline
-
Novartis (NVS) Tops Q2 EPS by 12c, Offers Outlook
-
Novartis delivers strong sales, double digit core operating income growth and launches Zolgensma and Piqray in second quarter; sales and profit guidance increased
-
Eric Bruno to lead North America commercial business at Dentsply Sirona
-
New Alcon DAILIES® COLORS Contact Lenses Give Beauty Lovers Permission to Play with Their Eye Color Every Day
-
Alcon Takes Center Stage with Contact Lens Innovations and the iLUX® System at the 2019 Optometry’s Meeting
-
Gymnast Laurie Hernandez and Alcon Help People See Their Potential with New “Eye Can, Eye Will” Campaign
-
Novartis highlights company transformation, catalyst-rich pipeline, and strong progress on strategy at Meet Novartis Management investor event
-
BVI Medical names Shervin Korangy as President and Chief Executive Officer
-
Alcon Reports First Quarter 2019 Trading Update
-
Alcon Reports First Quarter 2019 Trading Update
-
Acucela Appoints Robert “Bob” J. Stevens to its Board of Directors
-
Novartis buys dry eye drug from Takeda for up to $5.3 billion
-
Galimedix, Inc. Appoints Renowned Industry Veteran and Innovator in the Field of Ophthalmology Thomas Hohman, Ph.D. to Board of Directors
-
Galimedix, Inc. Appoints Renowned Industry Veteran and Innovator in the Field of Ophthalmology Thomas Hohman, Ph.D. to Board of Directors
-
Alcon to Showcase New Clinical Data, Innovative Technology at American Society of Cataract and Refractive Surgery 2019 Annual Meeting
-
Alcon to Showcase New Clinical Data, Innovative Technology at American Society of Cataract and Refractive Surgery 2019 Annual Meeting
-
uStudio Introduces First Live Audio Podcasts for Enterprise Communications
-
DURECT Appoints Two New Board Members
-
Novartis starts 2019 with strong sales and double digit core[1] operating income growth, Mayzent launch and Alcon spin-off; profit guidance upgraded
-
Berenberg Starts Alcon Inc. (ALC) at Hold
-
Bausch Health Companies (BHC) $41 PT Reiterated At Mizuho After A Post Novartis Spin SOTP Analysis
-
European stocks tick up post ECB decision, banks fall
-
Novartis (NVS) calls active on Alcon (ALC) eye care spin-off
-
Alcon (ALC) to Debut on NYSE Following Novartis Spin-Off

